• Explore /
  • Poster
  • / Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).

Abstract Poster

Authors

null

Robert W. Chen

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

Robert W. Chen , Stephen M. Ansell , Andrea Gallamini , Joseph M. Connors , Kerry J. Savage , Graham P. Collins , Andrew Grigg , Anna M. Sureda , Nilanjan Ghosh , Tatyana Feldman , Alexander Fosså , Evren Ozdemir , Fritz Offner , Gerald Engley , Keenan Fenton , Shih-Yuan Lee , Hina Jolin , Ashish Gautam , Martin Hutchings

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Hodgkin Lymphoma

Clinical Trial Registration Number

NCT01712490

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7539)

DOI

10.1200/JCO.2018.36.15_suppl.7539

Abstract #

7539

Poster Bd #

176

Abstract Disclosures

Similar Posters

First Author: Howland E. Crosswell

First Author: Scott F. Huntington

First Author: David J. Straus

First Author: Stephen Maxted Ansell